On Wednesday, 24 January 2018, the World Health Organization’s (WHO) Executive Board is expected to discuss agenda item 3.6 on Addressing the global shortage of, and access to, medicines and vaccines. Non-state actors in official relations with the WHO are… Continue Reading
In November 2017, the World Health Organization (WHO) published a report charting a path forward for the expansion of WHO’s work on the transparency of R&D costs and medicines prices while rekindling the prospects for WHO to assume the mantle of… Continue Reading
Attached is the Civil Society input to the 1st World Conference on Access to Medical Products and International Laws for Trade and Health in the context of the 2030 Agenda for Sustainable Development that took place in Delhi, India in… Continue Reading
Meeting: EB Special session on the draft Thirteenth General Programme of Work Agenda Item: 3. Draft Thirteenth General Programme of Work Statement: KEI welcomes the opportunity to comment on the 13th General Programme of Work anchored upon WHO’s vision of… Continue Reading
Email records and memoranda released by the Centers for Disease Control (CDC) in response to a Knowledge Ecology International Freedom of Information Act (FOIA) request show that representatives of the World Health Organization (WHO) and the United States government opposed including India’s proposed agenda item on the United Nations Secretary-General’s High-Level Panel on Access to Medicines for discussion at the 140th WHO Executive Board meeting.
The full set of documents, which was released to KEI without redaction, are available here:
On the morning of Monday, 23 January 2017, India delivered the following intervention at the 140th session of the World Health Organization’s Executive Board requesting the “explicit inclusion” of the United Nations Secretary-General’s High-Level Panel Report in the “provisional agenda of the EB140 as a separate agenda item under item 8.”
In making the case for the inclusion of the UN HLP in the WHO’s Executive Board deliberations, India articulate the following:
On Wednesday, 9 November 2016, the World Health Organization (WHO) delivered the following statement at the World Trade Organization’s (WTO) TRIPS Council’s discussions of the United Nations Secretary-General’s High Level Panel Report on Access to Medicines.
COUNCIL FOR TRIPS
8-9 NOVEMBER 2016
13. THE UNITED NATIONS SECRETARY-GENERAL’S HIGH LEVEL PANEL REPORT ON ACCESS TO MEDICINES
Thank you very much for giving WHO the opportunity to share our feedback on the Report of the High-Level Panel on Access to Medicines.
On Tuesday February 3, 2015, the final day of the 136th WHO Executive Board meeting, the EB passed a draft decision on the Global Strategy and Plan of Action on Public Health, Innovation, and Intellectual Property (GSPoA). The draft decision recommends to the WHA that the GSPOA be extended until 2022. Continue Reading
Another matter considered during the Friday, January 30th session of the WHO Executive Board was the “Follow-up of the report on the Consultative Expert Working Group on Research Development-Financing and Coordination.” In addition to the general report on the CEWG, the EB also considered the Director General’s report on the CEWG “Health research and development demonstration projects.”